Management of Early Severe Hypertension in Acute Intracerebral Hemorrhage in Primary Stroke Centers vs. Non-Stroke Center Hospitals (P01.022)

CONCLUSIONS: Antihypertensives were initiated earlier for ICH at PSCs, however steroid utilization was no different. This suggests that routing stroke patients to PSCs may improve timeliness of antihypertensive therapy for ICH and greater education requiring avoidance of steroids is desirable even within PSCs.Disclosure: Dr. Flinders has nothing to disclose. Dr. Sanossian has received personal compensation for activities with Boehringer-Ingelheim as speaker. Dr. Starkman has received research support from the National Institutes of Health, Lundbeck, Mitsubishi, and NTI. Dr. Liebeskind has received personal compensation for activities with Concentric Medical, Inc. and CoAxia, Inc as a consultant. Dr. Eckstein has nothing to disclose. Dr. Stratton has nothing to disclose. Dr. Pratt has nothing to disclose. Dr. Hamilton has nothing to disclose. Dr. Olivas has nothing to disclose. Dr. Sanossian has received personal compensation for activities with Boehringer-Ingelheim as speaker. Dr. Conwit has nothing to disclose. Dr. Saver has received personal compensation for activities with The University of California, Regents as a scientific consultant to BrainsGate, CoAxia, ev3, Talecris, PhotoThera, and Sygnis. Dr. Saver has received research support from the University of California, Regents,

Source: Neurology - February 14, 2013 Category: Neurology Authors: Flinders, A., Sanossian, N., Starkman, S., Liebeskind, D., Eckstein, M., Stratton, S., Pratt, F., Hamilton, S., Olivas, E., Chatfield, F., Conwit, R., Saver, J. Tags: P01 Neurocritical Care: Clinical Neurophysiology/Therapeutics Source Type: research